Key Findings
The North America market for contraceptive is estimated to grow from $XX billion in 2018 to $XX billion by 2027, at a CAGR of 6.49% between 2019 and 2027. North America dominated the overall market in terms of revenue and the United States market held the largest market share over the forecast period.

Market Insights
The rising customer awareness and government initiatives, the growing incidence of unwanted pregnancies and the swelling occurrence of sexually transmitted diseases (STD) are the chiefly driving the market growth in the region.

North America comprises three countries, namely, the United States and Canada. It has experienced a minimal change in the contraceptive methods use rates, and the usage has decreased by XX%. However, the region has the highest contraceptive prevalence, around XX%. Effective contraceptive methods such as pills, male condoms, IUDs, injectable, implants, and other modern barrier methods dominate this region.

Competitive Insights
Mayer Laboratories, Inc., OCON Medical Ltd., Afaxys, Inc., Bayer AG, Reckitt Benckiser PLC, Agile Therapeutics, Teva Pharmaceutical Industries Ltd., Pregna, Allergan Inc., Merck & Co., Inc., Church & Dwight Co., Inc., Cooper Surgical Inc., Pfizer, Inc., Okamoto Industries, Inc., and Apothecus Pharmaceutical Corporation are the major contending market players operating in North America, which have been profiled with intricate details in the report.